Do not increased insulin secretion.
Stimulate beta cells of the pancreas.
Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels.
Sensitize body tissue to insulin: stimulates insulin receptor sites.
Stimulate pancreas to secrete insulin.
Possible side-effect of impaired platelet function.
Inhibit production of glucose by the liver.
Prevents kidneys from reabsorbing glucose.
Drug to drug interaction with NSAIDS.
Usually given once a day.
Enhances glucose-dependent insulin secretion.
Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus)
Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia)
Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance)
glipizide
Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl)
Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix)
Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity)
Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset)
Avandia
Januvia
Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance
